Cell and Gene Commercialization

  1. Combination Cell Therapy's Clinical Success Hinges On Manufacturability 8/5/2026

    Cell therapy could help unlock checkpoint inhibitors’ potential in solid tumors, but combination regimens raise the bar for manufacturing consistency and scalability.

  2. The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue 7/21/2026

    AI can close CAR-T’s access gap by replacing fragmented community delivery handoffs with automated orchestration across referral, reimbursement, logistics, and monitoring.

  3. Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors 7/17/2026

    US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.

  4. Let's Stop Treating Allogeneic Cell Therapy As One Thing 7/14/2026

    Industry is beginning to accept that allogeneic cell therapy spans categories, and success depends on aligning biology, regulation, and economics unique to each product.

  5. FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy 7/9/2026

    Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.

  6. Cell & Gene: The Podcast Presents: Better Biopharma's Editors' Roundtable — A Midyear Look at the 2026 Life Sciences Industry 6/15/2026

    For episode 131 of Cell & Gene: The Podcast, we’re sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues.

  7. Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT 6/2/2026

    Gene therapy’s next test is not proving it works, but proving it can scale.

  8. Cell And Gene Therapies – U.S. Payer Trends 5/20/2026

    Gain insights from U.S. payer interviews covering coverage processes, evidence requirements, and engagement strategies to accelerate market access from late-stage development through commercialization.

  9. Price Matters - Why Dash Believes In Transparency 5/15/2026

    Opaque pricing slows decisions and erodes trust. Transparency clarifies cost drivers, improves budgeting, enables confident sourcing, and strengthens long-term R&D partnerships.

  10. Can A Biotech Create A CDMO Market? 5/11/2026

    Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.